| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NFKBIB |
| Uniprot No | Q15653 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-356aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMAGVAC LGKAADADEW CDSGLGSLGP DAAAPGGPGL GAELGPGLSW APLVFGYVTE DGDTALHLAV IHQHEPFLDF LLGFSAGTEY MDLQNDLGQT ALHLAAILGE TSTVEKLYAA GAGLCVAERR GHTALHLACR VGAHACARAL LQPRPRRPRE APDTYLAQGP DRTPDTNHTP VALYPDSDLE KEEEESEEDW KLQLEAENYE GHTPLHVAVI HKDVEMVRLL RDAGADLDKP EPTCGRSPLH LAVEAQAADV LELLLRAGAN PAARMYGGRT PLGSAMLRPN PILARLLRAH GAPEPEGEDE KSGPCSSSSD SDSGDEGDEY DDIVVHSSRS QTRLPPTPAS KPLPDDPRPV |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及NFKBIB重组蛋白研究的文献概述：
1. **"Functional analysis of recombinant IκB-β inhibitor in NF-κB signaling"**
*作者：Chen Z, et al.*
摘要：研究通过大肠杆菌表达系统重组表达人源NFKBIB蛋白，验证其抑制NF-κB p65亚基核转位的功能，并发现其磷酸化位点突变体对炎症因子刺激的敏感性降低。
2. **"Structural characterization of IκB-β/NF-κB complex by cryo-EM"**
*作者：Chen Y, et al.*
摘要：利用重组NFKBIB蛋白与p50/p65异源二聚体进行复合物组装，通过冷冻电镜解析了IκBβ结合NF-κB的分子机制，揭示了其与IκBα不同的结合模式。
3. **"Recombinant IκBβ protein enhances chemotherapy sensitivity in breast cancer cells"**
*作者：Wang L, et al.*
摘要：在乳腺癌细胞中过表达重组NFKBIB蛋白，发现其通过抑制NF-κB活性增加癌细胞对阿霉素的敏感性，表明其在肿瘤治疗中的潜在应用价值。
注：以上文献名为模拟标题，实际研究需通过PubMed或Web of Science以关键词"NFKBIB recombinant"检索近年发表的具体论文。
NFκBIB (Nuclear Factor Kappa B Inhibitor Beta), also known as IκBβ, is a member of the IκB family of proteins that regulate the activity of NF-κB transcription factors. NF-κB plays a central role in immune responses, inflammation, apoptosis, and cell proliferation by controlling the expression of target genes. Under resting conditions, NF-κB is sequestered in the cytoplasm through direct binding to inhibitory IκB proteins, including NFKBIB. Upon stimulation by cytokines, pathogens, or stress signals, IκB proteins are phosphorylated and degraded via the ubiquitin-proteasome pathway, allowing NF-κB to translocate into the nucleus and activate gene transcription.
Recombinant NFKBIB proteins are engineered in vitro to study its structural and functional interactions with NF-κB. These proteins are typically produced using expression systems such as *E. coli* or mammalian cell lines, enabling high-purity yields for biochemical assays. Recombinant NFKBIB retains the ability to bind NF-κB subunits (e.g., p50/p65 heterodimers) and inhibit their DNA-binding activity, making it a valuable tool for dissecting NF-κB signaling mechanisms. Researchers utilize it in pull-down assays, co-immunoprecipitation, and structural studies (e.g., X-ray crystallography) to map interaction domains or analyze regulatory post-translational modifications.
Dysregulation of NFKBIB is linked to inflammatory diseases, cancer, and autoimmune disorders. Recombinant NFKBIB has been employed in drug screening platforms to identify compounds that modulate the NF-κB pathway, offering potential therapeutic strategies. Additionally, it aids in studying feedback loops, as NFKBIB expression itself is induced by NF-κB, creating dynamic regulatory networks. Its recombinant form provides a standardized reagent for reproducible research, bridging gaps in understanding NF-κB-driven pathologies and targeted interventions.
×
